An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastasesCaroline Dutriaux, Philippe Saïag, Charlée Nardin et al.|European Journal of Cancer|2022Cited by 13
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenibPhilippe Saïag, Caroline Dutriaux, Charlée Nardin et al.|European Journal of Cancer|2021Cited by 13
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Alexander C. J. van Akkooi, Bastian Schilling et al.|The Lancet Oncology|2025Cited by 10
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced <i>BRAF</i>-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).Caroline Robert, Alexander Christopher Jonathan Van Akkooi, Bastian Schilling et al.|Journal of Clinical Oncology|2024Cited by 8
Management of metastatic uveal melanoma: French expert consensus guidelinesManuel Rodrigues, Sophie Piperno‐Neumann, Vincent Servois et al.|Bulletin du Cancer|2025Cited by 3